TY - JOUR
T1 - Preloaded combination nicotine replacement therapy for smoking cessation in Kazakhstan
T2 - A randomized controlled trial study protocol
AU - Purushothama, Chethan
AU - Crape, Byron Lawrence
AU - Stolyarov, Valentina
AU - Jaxybayeva, Altynshash
AU - La Fleur, Philip
AU - Olickal, Jeby Jose
N1 - Publisher Copyright:
© 2023 Purushothama et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2023/11
Y1 - 2023/11
N2 - Background Tobacco use is a major cause of premature death and disease in Kazakhstan, with over 22,500 deaths per year. Although efforts have been made to control tobacco use, smokingrelated deaths have continued to increase. One strategy to help smokers quit is to use nicotine replacement therapy (NRT), with combination NRT resulting in higher long-term quit rates than a single form of NRT. A study aims to determine the effectiveness of preloaded combination NRT on smoking cessation, the change in health-related quality of life due to smoking cessation, and explore treatment adherence perceptions. Methods and analysis The study will be conducted as a randomized, single-blind superiority trial, with 100 participants in each arm. The trial will be carried out at the National Research Cardiac Surgery Center, Astana, Kazakhstan, and will recruit current smokers aged 18 years and above with a motivation to quit. Participants will be randomly allocated to either the intervention group or the control group. The former will receive preloaded combination NRT, while the latter will receive fast-acting NRT alone. The primary outcome measure will be sustained abstinence from smoking after six months. Secondary outcome measures will include health-related quality of life and adherence to the treatment. Discussion The study may gather further evidence that a combination NRT is more efficient than a fastacting NRT alone. The findings of this study may help to improve tobacco cessation strategies in Kazakhstan and other countries with high smoking prevalence rates.
AB - Background Tobacco use is a major cause of premature death and disease in Kazakhstan, with over 22,500 deaths per year. Although efforts have been made to control tobacco use, smokingrelated deaths have continued to increase. One strategy to help smokers quit is to use nicotine replacement therapy (NRT), with combination NRT resulting in higher long-term quit rates than a single form of NRT. A study aims to determine the effectiveness of preloaded combination NRT on smoking cessation, the change in health-related quality of life due to smoking cessation, and explore treatment adherence perceptions. Methods and analysis The study will be conducted as a randomized, single-blind superiority trial, with 100 participants in each arm. The trial will be carried out at the National Research Cardiac Surgery Center, Astana, Kazakhstan, and will recruit current smokers aged 18 years and above with a motivation to quit. Participants will be randomly allocated to either the intervention group or the control group. The former will receive preloaded combination NRT, while the latter will receive fast-acting NRT alone. The primary outcome measure will be sustained abstinence from smoking after six months. Secondary outcome measures will include health-related quality of life and adherence to the treatment. Discussion The study may gather further evidence that a combination NRT is more efficient than a fastacting NRT alone. The findings of this study may help to improve tobacco cessation strategies in Kazakhstan and other countries with high smoking prevalence rates.
UR - http://www.scopus.com/inward/record.url?scp=85178024208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178024208&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0292490
DO - 10.1371/journal.pone.0292490
M3 - Article
C2 - 38011129
AN - SCOPUS:85178024208
SN - 1932-6203
VL - 18
JO - PLoS ONE
JF - PLoS ONE
IS - 11 November
M1 - e0292490
ER -